Anchalee Avihingsanon1,2, Gail V Matthews3,4, Sharon R Lewin5,6,7, Pip Marks3, Jose Sasadeusz5,8, David A Cooper3, Scott Bowden9, Stephen Locarnini9, Greg J Dore3, Kiat Ruxrungtham1,2. 1. HIV-NAT Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 2. Division of Allergy and Clinical Immunology, Faculty of Medicine, Bangkok, Thailand. 3. The Kirby Institute for infection and immunity in society, University of New South Wales, Sydney, Australia. 4. The Kirby Institute for infection and immunity in society, University of NSW, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. 5. Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia. 6. Department of Medicine, Monash University, Melbourne, Australia. 7. Centre for Virology, Burnet Institute, Melbourne, Australia. 8. Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia. 9. Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
Abstract
BACKGROUND:Hepatic Flare (HF) after initiation of highly active antiretroviral therapy (HAART) in HIV-HBV coinfected individuals is well recognized but prospective data on predictors and subsequent outcome are limited. METHODS: The Tenofovir in HIV-HBV coinfection study was a randomized clinical trial of HBV-active HAART including lamivudine and/or tenofovir in antiretroviral naïve HIV-HBV individuals in Thailand. RESULTS:Early HF (EHF) was defined as ALT > 5 × ULN during the first 12 weeks. EHF was observed in 8 (22%) of individuals at a median of 56 days. 6/8 EHF cases were asymptomatic and resolved with HAART continuation, however one subject with underlying cirrhosis died following rapid hepatic decompensation. EHF was significantly associated with higher baseline ALT (79 IU/L vs 36 IU/L non-EHF, p = 0.008) and HBV DNA (9.9 log10 c/ml vs 8.4 log10 c/ml non EHF, p = 0.009), and subsequent serological change. HBeAg loss occurred in 75% of EHF cases versus 22% in non-EHF (p = 0.04), and HBsAg loss in 25% of EHF cases versus 4% of non-EHF (p = 0.053). CONCLUSION:EHF after HBV active HAART initiation was frequently observed in this population. Timing of EHF, association with elevated ALT and HBV DNA and high rate of seroconversion are all consistent with immune restoration as the likely underlying process. CLINICAL TRIAL NUMBER: NCT00192595.
RCT Entities:
BACKGROUND: Hepatic Flare (HF) after initiation of highly active antiretroviral therapy (HAART) in HIV-HBV coinfected individuals is well recognized but prospective data on predictors and subsequent outcome are limited. METHODS: The Tenofovir in HIV-HBV coinfection study was a randomized clinical trial of HBV-active HAART including lamivudine and/or tenofovir in antiretroviral naïve HIV-HBV individuals in Thailand. RESULTS: Early HF (EHF) was defined as ALT > 5 × ULN during the first 12 weeks. EHF was observed in 8 (22%) of individuals at a median of 56 days. 6/8 EHF cases were asymptomatic and resolved with HAART continuation, however one subject with underlying cirrhosis died following rapid hepatic decompensation. EHF was significantly associated with higher baseline ALT (79 IU/L vs 36 IU/L non-EHF, p = 0.008) and HBV DNA (9.9 log10 c/ml vs 8.4 log10 c/ml non EHF, p = 0.009), and subsequent serological change. HBeAg loss occurred in 75% of EHF cases versus 22% in non-EHF (p = 0.04), and HBsAg loss in 25% of EHF cases versus 4% of non-EHF (p = 0.053). CONCLUSION: EHF after HBV active HAART initiation was frequently observed in this population. Timing of EHF, association with elevated ALT and HBV DNA and high rate of seroconversion are all consistent with immune restoration as the likely underlying process. CLINICAL TRIAL NUMBER: NCT00192595.
Authors: M den Brinker; F W Wit; P M Wertheim-van Dillen; S Jurriaans; J Weel; R van Leeuwen; N G Pakker; P Reiss; S A Danner; G J Weverling; J M Lange Journal: AIDS Date: 2000-12-22 Impact factor: 4.177
Authors: J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown Journal: N Engl J Med Date: 1999-10-21 Impact factor: 91.245
Authors: C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari Journal: J Clin Invest Date: 1998-09-01 Impact factor: 14.808
Authors: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan Weel; Suzanne Jurriaans; Joep M A Lange Journal: J Infect Dis Date: 2002-06-14 Impact factor: 5.226
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988
Authors: M Welz; S Eickhoff; Z Abdullah; J Trebicka; K H Gartlan; J A Spicer; A J Demetris; H Akhlaghi; M Anton; K Manske; D Zehn; B Nieswandt; C Kurts; J A Trapani; P Knolle; D Wohlleber; W Kastenmüller Journal: Nat Commun Date: 2018-11-15 Impact factor: 14.919
Authors: Marco Iannetta; Angela M A Crea; Andrea Di Lorenzo; Laura Campogiani; Elisabetta Teti; Vincenzo Malagnino; Mirko Compagno; Luigi Coppola; Lorenzo Piermatteo; Giampiero Palmieri; Carolina Cimino; Romina Salpini; Maria A Zingaropoli; Maria R Ciardi; Claudio M Mastroianni; Saverio G Parisi; Valentina Svicher; Massimo Andreoni; Loredana Sarmati Journal: Open Forum Infect Dis Date: 2022-08-29 Impact factor: 4.423
Authors: Bruno Bezerril Andrade; Katherine Huppler Hullsiek; David R Boulware; Adam Rupert; Martyn A French; Kiat Ruxrungtham; Marisa Luisa Montes; Huw Price; Pablo Barreiro; Jennifer Audsley; Alan Sher; Sharon R Lewin; Irini Sereti Journal: J Infect Dis Date: 2013-01-18 Impact factor: 5.226
Authors: Marc M Solomon; Mauro Schechter; Albert Y Liu; Vanessa M McMahan; Juan V Guanira; Robert J Hance; Suwat Chariyalertsak; Kenneth H Mayer; Robert M Grant Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731